Navigation Links
Tepnel Shareholders Approve Acquisition by Gen-Probe
Date:3/16/2009

SAN DIEGO, March 16 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced that shareholders of Tepnel Life Sciences, PLC (AIM: TED) approved the acquisition of Tepnel by Gen-Probe by the requisite majorities at Court and General Meetings held in London earlier today.

More than 99% of Tepnel shareholders voted in favor of the acquisition, which was first announced on January 30, 2009 and is structured as a "scheme of arrangement" under English law. The transaction is expected to close on or around April 8, pending additional court proceedings.

Additional information about today's meetings can be found on the investor relations section of Tepnel's website at: http://miranda.hemscott.com/servlet/HsPublic?context=ir.access.jsp&ir_client_id=2374&ir_option=RNS_HEADLINES&transform=investor_home&links=home&disclaimer=prices&side=shareprice.

Discussion of Dealing Disclosure Requirements Under UK Law

Under the provisions of Rule 8.3 of the UK Takeover Code (the "Code"), if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Tepnel, all "dealings" in any "relevant securities" of that company (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than 3:30 pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, un
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
2. Leading Proxy Advisory Firm RiskMetrics Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group
3. Tyco to Host 2009 Annual General Meeting and Special General Meeting of Shareholders
4. Glass Lewis Recommends Shareholders Support LCA-Vision Board of Directors and Reject All Three Proposals by Dissident Joffe Group
5. NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
6. MedClean Technologies Inc. CEO Publishes Letter to Shareholders
7. Cell Therapeutics Updates Shareholders on Trading
8. Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter
9. Phyhealth Provides Update to Shareholders
10. Prime Companies Reaches Agreement to Spin Off Subsidiary; Shareholders Gain 15 Percent Stake in New Telecommunications Company
11. Amilpar - Notice to Shareholders - Distribution of Interest on Capital Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... The Capital Institute for Neurosciences at Capital Health ... a clinical trial that delivers chemotherapy to brain tumors ... the procedure, done at Capital Health Medical Center – ... tiny catheter through the patient’s femoral artery in the ... the brain. Once the catheter reached the brain, chemotherapy ...
(Date:7/10/2014)... Colorado (PRWEB) July 10, 2014 ... will gather in Copenhagen this July 13-17 to ... bringing the world closer to breakthroughs in dementia ... the world’s largest conference of its kind. , ... AAIC serves as a catalyst for generating new ...
(Date:7/10/2014)... 10, 2014 In his latest blog ... drug treatment facility CEO Per Wickstrom has listed 5 ... trying to confirm an appointment, get information or sometimes ... following-up without being annoying is a skill that most ... a way to keep the dialogue moving without coming ...
(Date:7/10/2014)... (July 8, 2014) A new study from Colorado ... improvements, poor oral health remains a major problem in ... "The oral health among Native Americans is abysmal with ... of the country," said Terrence Batliner, DDS, MBA, associate ... at the School of Public Health. "The number one ...
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Teens who ... are more likely to develop emotional symptoms such as ... factors such as these that may exacerbate issues teens ... appropriate treatment and in making decisions about when to ... school for these athletes," study authors Lisa Koehl and ...
Breaking Medicine News(10 mins):Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 2Health News:New Trial Delivers Chemotherapy to Brain Tumor Through Artery in Leg 3Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Some Teens May Face Emotional Problems After Concussion 2
... 26 Velos, Inc., the recognized leader and ... and Net.Orange, Inc., the respected healthcare Internet solutions ... Cancer Research Centers (Mary Crowley). The two companies ... for strong central clinical research infrastructure and implementation ...
... Sandals(R) Originals2 Footwear by BeechHUNTINGTON BEACH, Calif., Feb. ... Yoga Sandals(R) Originals line with new adjustable ... This patented foot therapy can now be customized ... foot , increasing flexibility and helping improve balance ...
... LLC ( http://www.GlenwoodSystems.com ) launches the GlaceComplete product suite which seamlessly ... an assisted medical billing process. The product has been designed ... maximizing revenue contribution for the average office based medical practice. ... ...
... Today, AmeriGlide announced the recipient of this years AmeriGlide Achiever Scholarship. ... a wheelchair. , ... Raleigh, NC (PRWEB) February 26, ... of the first semi-annual AmeriGlide Achiever Scholarship. The AmeriGlide Achiever Scholarship ...
... Honored for Comebacks from Ostomy SurgeryWASHINGTON, Feb. 25 ... improving the lives of other ostomates, was named this ... pilot Robert (Bob) Cuyler was named the first recipient ... ceremony here this evening. Founded in 1984 by ...
... ArvinMeritor (NYSE: ARM ) today announced that ... by Lin Cummins, senior vice president of Communications for ArvinMeritor, ... one of the most challenging economic times in history, I ... and individuals to help wipe out heart disease, the number ...
Cached Medicine News:Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 2Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 3Health News:Mary Crowley Cancer Research Centers Achieve Dramatic Improvements in Financial Infrastructures With Velos eResearch and Net.Orange Systems 4Health News:Sandal Evolution(R) Takes a Healthy Step 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 2Health News:Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete 3Health News:AmeriGlide Announces Recipient of AmeriGlide Achiever Scholarship 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 2Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 3Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 4Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 5Health News:Great Comebacks(R) Program Announces 2008 National Award Winner and Inaugural Tony Snow Public Service Award 6Health News:ArvinMeritor Proud to Sponsor American Heart Association Campaign 2
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... - Bentley,Pharmaceuticals, Inc. (NYSE: BNT), a specialty ... abstract sponsored by,the Company has been accepted ... Association 67th Scientific Sessions in Chicago.,The abstract, ... Comparison Study of Intranasal Insulin Spray,(Nasulin(TM)) and ...
... Among Patients with,Active Disease, MOUNTAIN VIEW, ... Inc., a clinical-stage biopharmaceutical company,focused on ... target the chemokine system,presented data today ... trial of,Traficet-EN (CCX282-B), an orally-active anti-inflammatory ...
Cached Medicine Technology:Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 2Bentley Late Breaking Abstract Accepted for Poster Presentation at,American Diabetes Association Scientific Sessions 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 2ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 3ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 4ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference 5
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
Medicine Products: